

## DAFTAR PUSTAKA

AACR 101<sup>st</sup> Annual Meeting, Philadelphia, 2010, “U6 Upregulation in Cancer”,  
Hwang, L., Lin, X., Desai, N., Trieu, V., Washington D.C.: OASIS.

Allday, M. J., Crawford, D. H., Thomas J. A., 1993, “Epstein-Barr Virus (EBV)  
Nuclear Antigen 6 Induces Expression of The EBV Latent Membrane  
Protein and an Activated Phenotype in Raji Cells”, *Journal of General  
Virology*, 74: 361-369.

American Cancer Society, 2015, Targeted Therapy (internet),  
<[http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes  
/targetedtherapy/targeted-therapy-toc](http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/targetedtherapy/targeted-therapy-toc)> (diakses 17 Maret 2015).

Anonim, 2007, Doxil Product Information (internet),  
<[www.doxil.com/shared/product/doxil/prescribing-information.pdf](http://www.doxil.com/shared/product/doxil/prescribing-information.pdf)>  
(diakses: 1 April 2014).

Appaiah, H. N., Chirayu, P. G., Lida, A. M., Sunil, B., George, W. S., Yunlong,  
L., Harikrishna, N., 2011, “Persistent Upregulation of U6:SNORD44  
Small RNA Ratio in The Serum of Breast Cancer Patients”. *Breast Cancer  
Research*, 13(5):R86.

Aragec dan Duffy, 2015, ABC Staining (internet),  
<<http://aragec.com/abc+y%C3%B6ntemi.html>> (diakses: 13 Maret 2015).

Bader, A. G., Brown, D., Stoudemire, J., Lammers, P., 2011, “Developing  
Therapeutic microRNAs for Cancer”, *Gene Therapy*, 18:1121–1126.

Bai, H., Wei, J., Deng, C., Yang, X., Wang, C., Xu, R., 2013, “*microRNA-21*  
Regulates The Sensitivity of Diffuse Large B-Cell Lymphoma Cells to  
The CHOP Chemotherapy Regimen”. *Int J Hematol.*, 97(2):223–231.

Baltic, V., Baltic, M., Svircev, Z., Patric, V.J., 2008, “microRNA Expression in  
Non Hodgkin’s Lymphomas”, *Arch Oncol.*, 16(3-4):59-68.

Barakzai, M.A. dan Pervez, S., 2009, “CD20 Positivity in Classical Hodgkin's  
Lymphoma: Diagnostic Challenge or Targeting Opportunity”, *Indian J  
Pathol Microbiol.*, 52(1):6-9.

Bartels. C. L. dan Tsongalis, G. J., 2009, “MicroRNAs: Novel Biomarkers for  
Human Cancer”, *Clinical Chemistry* 55(4): 623-31.

- Basu, G., 2011, “Antibody Based Detection of Biomarkers Predicting Response to Taxanes in Breast Cancer Patients”, *J Mol Biomark Diagn.*, 3:4.
- Benz, F., Roderburg, C., Vargas, C. D., Vucur, M., Gautheron, J., Koch, A., Zimmermann, H., Janssen, J., Nieuwenhuijsen, L., Luedde, M., Frey, N., Tacke, F., Trautwein, C., Luedde, T., 2013, “U6 is Unsuitable for Normalization of Serum miRNA Levels in Patients with Sepsis or Liver Fibrosis”, *Exp Mol Med.*, 20(45):e42.
- Bhardwaj, A, Singh S., Singh A. P., 2010. “MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs”, *Mol Cell Pharmacol* 2(5):213-219.
- Bower, N.I., Moser, R. J., Hill, J. R., Lehnert, S. A., 2007, “Universal Reference Method for Real-Time PCR Gene Expression Analysis of Preimplantation Embryos”, *BioTechniques*, 42(2):199–206.
- Bruton, L., Lazo, J. S., Parker, K. L., 2005, *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 11<sup>th</sup> Edition, McGrawHill, Lange.
- Burgess, D.J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W.R., Hannon, G.J., Lowe, S.W., Hemann, M.T., 2008, “Topoisomerase Levels Determine Chemotherapy Response In Vitro and In Vivo”. *Proc Natl Acad Sci USA*, 105(26):9053-8.
- Bustin, S. A. dan Nolan, T., 2004, “Pitfalls of Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction”, *J Biomol Tech.*, 15(3):155-66.
- Calloire F. dan Fabbri M., 2010, MicroRNAs and Cancer (internet), <<http://atlasgeneticsoncology.org/Deep/MicroRNAandCancerID20101.html>> (diakses: 8 Agustus 2014).
- Cancer Research UK, 2012, Annual Report and Account (internet), <[www.cancerresearchuk.org](http://www.cancerresearchuk.org)> (diakses: 1 April 2014).
- Catuogno, S., Esposito, C. L., Quintavalle, C., Cerchia, L., Condorelli, G., de Franciscis, V., 2011, “Recent Advance in Biosensors for microRNAs Detection in Cancer”, *Cancers (Basel)*, 3(2): 1877–1898.
- Chang., C-J., Mulholland, D.J., Valamehr, B., Mosessian, S. S., William, R., Wu, H., 2008, “PTEN Nuclear Localization Is Regulated by Oxidative Stress and Mediates p53-Dependent Tumor Suppression”, *Molecular and Cellular Biology*, 28(10): 3281–3289.
- Dalmay, T. dan Edwards D. R., 2006, “MicroRNAs and The Hallmarks of Cancer”, *Oncogene*, 25:6170–6175.

Delecluse, H., Hilsendegen, T., Pich, D., Zeidler, R. Hammerschmidt, W., 1998, “Propagation and Recovery of Intact, Infectious Epstein–Barr Virus from Prokaryotic to Human Cells”, *PNAS*, 95 (14) 8245-8250.

Ebada, E.S., Edrada, R.U., Lin, W., Proksch, P., 2008, “Methods for Isolation, Purification and Structural Elucidation of Bioactive Secondary Metabolites from Marine Invertebrates”, *Nature Protocols*, 3 (12): 1820-1831.

Ebert, M.S. dan Sharp, P.A., 2010, “microRNA Sponges: Progress and Possibilities”. *RNA*, 16(2):2043–2050.

Epstein, M.A. dan Barr Y.M., 1964, “Cultivation In Vitro of Human Lymphoblast from Burkitt’s Malignant Lymphoma”, *The Lancet*, 283:252 – 253.

Etheridge A., Lee I., Hood L., Galas D., Wang K., 2011, “Extracellular MicroRNA: A New Source of Biomarkers”, *Mutation Research*, MUT-11038: 6.

External RNA Controls Consortium, 2005, “Proposed Methods for Testing and Selecting The ERCC External RNA Controls”, *BMC Genomics*, 6:150.

Fardin, P., Moretti, S., Biasotti, B., Ricciardi, A., Bonassi, S., Varesio, L., 2007, “Normalization of Low-Density Microarray using External Spike-in Controls: Analysis of Macrophage Cell Lines Expression Profile”, *BMC Genomics*, 8: 17.

Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., mathers C., Rebelo M., Parkin D.M., Forman D., Bray F., 2012, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer (internet), <<http://globocan.iarc.fr.>> (diakses: 11 April 2014).

Ferracin, M., Zagatti, B., Rizzotto, L., Cavazzini, F., Veronese, A., Ciccone, M., Saccenti, E., Lupini, L., Grilli, A., De Angeli, C., Negrini, M., Cuneo, A., 2010, “MicroRNAs Involvement in Fludarabine Refractory Chronic Lymphocytic Leukemia”, *Mol Cancer*, 9: 123.

Fojo T., 2007, “Multiple Paths to a Drug Resistance Phenotype: Mutations, Translocations, Deletions and Amplification of Coding Genes or Promoter Regions, Epigenetic Changes and MicroRNAs”, *Drug Res Update*, 10:59–67.

Freshney, R.I., 2000, Culture of Animal Cells: a Manual of Basic Technique Fourth Edition, Toronto: John Wiley & Sons, Inc.

- García M.G., Alaniz L.D., Cordo Russo R.I., Alvarez E., Hajos S.E., 2009, "PI3K/Akt Inhibition Modulates Multidrug Resistance and Activates NF-KappaB in Murine Lymphoma Cell Lines", *Leuk Res.*, 33(2):288-96.
- George G.P. dan Mittal R.D., 2010, "MicroRNAs: Potential Biomarkers in Cancer", *Indian Journal of Clinical Biochemistry*, 25 (1): 4-14.
- Glasspool R.M., Teodoridis J.M., Brown R., 2006, "Epigenetics as a Mechanism Driving Polygenic Clinical Drug Resistance", *Br J Cancer*, 94:1087.
- Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., Song, E., 2011, "Up-Regulation of *miR-21* Mediates Resistance to Trastuzumab Therapy for Breast Cancer", *J Biol Chem.*, 286(21):19127-37.
- Goto S., Ihara Y., Urata Y., Izumi S., Abe K., Koji T., Kondo T., 2001, "Doxorubicin-Induced DNA Intercalation and Scavenging by Nuclear Glutathione S-Transferase pi", *FASEB J.*, 15(14):2702-14.
- Gu, L., Song, G., Chen, L., Nie, Z., He, B., Pan, Y., Xu, Y., Li, R., Gao, T., Cho, W.C., Wang, S., 2013, "Inhibition of *miR-21* Induces Biological and Behavioral Alterations in Diffuse Large B-cell Lymphoma", *Acta Haematol.*, 130(2):87-94.
- Gutiérrez, M. L., Guevara, J., Barrera, L. A., 2012, "Semi-Automatic Grading System in Histologic and Immunohistochemistry Analysis to Evaluate *In Vitro* Chondrogenesis", *Universitas Scientiarum*, 17(2): 167-178.
- Haraguchi, T., Ozaki, Y., Iba, H., 2009, "Vectors Expressing Efficient RNA Decoys Achieve the Long-Term Suppression of Specific microRNA Activity in Mammalian Cells", *Nucleic Acids Res.*, 37: e43.
- Haryana, S.M., Aryandono, T., Astuti, I., 2013, "Laporan Kemajuan Kegiatan Penelitian Unggulan Perguruan Tinggi: Analisa Profil *microRNA 451* dan *21* pada Sel Lini MCF-7 dan Raji Resistensi Doxorubicin", LPPM, UGM.
- Hoffman, M., Wei, L. Y., Roepe, P., 1996, "Are Altered pH<sub>i</sub> and Membrane Potential in Hu MDR1 Transfectants Sufficient to Cause Protein-Mediated Multi Drug Resistance?", *J. Gen. Physiol.*, 108:295-313.
- Housman G., Shannon B., Sarah H., Karolina L., McKenna L., Nicole S., Sibaji S., 2014, "Drug Resistance in Cancer: An Overview", *Cancers*, 6:1769-1792.
- Johnson, S.A., Dubeau L., Johnson D.L., 2008, "Enhanced RNA Polymerase III-Dependent Transcription is Required for Oncogenic Transformation", *J Biol Chem.*, 283:19184–19191.

- Johnston S.T., Gallaher, Z.R., Czaja, K., 2012, “Exogenous Reference Gene Normalization for Real-Time Reverse Transcription-Polymerase Chain Reaction Analysis Under Dynamic Endogenous Transcription”, *Neural Regen Res.*, 7(14):1064-1072.
- Judelson, H., 2014, Primer Guidelines (internet). [<oomyceteworld.net/protocols/primer%20designing2.pdf>](http://oomyceteworld.net/protocols/primer%20designing2.pdf) (diakses: 11 April 2014).
- Katayama, K., Noguchi, K., Sugimoto, Y., 2014, “Regulations of P-Glycoprotein/ABCB1/*MDR1* in Human Cancer Cells”, *New Journal of Science*, Volume 2014, Article ID 476974.
- Katayama, K., Yoshioka, S., Tsukahara, S., Mitsuhashi, J., Sugimoto, Y., 2007, “Inhibition of The Mitogen-Activated Protein Kinase Pathway Results in The Down-Regulation of P-glycoprotein”, *Mol Cancer Ther.*, 6(7):2092–2102.
- Kemenkes. 2013. Seminar Sehari Dalam Rangka Memperingati Hari Kanker Sedunia 2013 (internet), [< www.depkes.go.id >](http://www.depkes.go.id) (diakses: 1 April 2014).
- Kosaka, N., Iguchi H., dan Ochiya T., 2010, “Circulating microRNA in Body Fluid: a New Potential Biomarker for Cancer Diagnosis and Prognosis”, *Cancer Sci.*, 101(10): 2087–2092.
- Kumar, A., Rajendran, V., Sethumadhavan, R., Purohit, R., 2013, “AKT Kinase Pathway: A Leading Target in Cancer Research”, *The ScientificWorld Journal*, vol. 2013, Article ID 756134, 6 pages.
- Lackner, M.R., Wilson, T.R., Settleman, J., 2012, “Mechanisms of Acquired Resistance to Targeted Cancer Therapy”, *Future Oncol.*, 8(8):999-1014.
- Lawrie, C. H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A.P., Pulford, K., Banham, A.H., Pezzela, F., Boulwood, J., Wainscoat, J.S., Christian, S., Hatton, R., Harris, A.L., 2008, “Detection of Elevated Levels of Tumour-Associated microRNAs in Serum of Patients with Diffuse Large B-Cell Lymphoma”, *British Journal of Haematology*, 141, 672–675.
- Leupin, N., Cenni, B., Novak, U., Hügli, B., Graber, H.U., Tobler, A., Fey, M.F., 2003, “Disparate Expression of The PTEN Gene: a Novel Finding in B-cell Chronic Lymphocytic Leukaemia (B-CLL)”, *Br J Haematol.*, 121: 97-100.
- Li, P., Mao W.M., Zheng Z.G., 2013, “Down-Regulation of PTEN Expression Modulated by Dysregulated *miR-21* Contributes to The Progression of Esophageal Cancer”, *Dig Dis Sci.*, 58(12):3483.

- Li, Z. dan Rana, T. M., 2014, "Therapeutic Targeting of microRNAs: Current Status and Future Challenges", *Nat. Rev. Drug Discov.*, 13: 622–638.
- Liang X. dan Huang, Y., 2001, "Alteration of Membrane Lipid Biophysical Properties and Resistance of Human Lung Adenocarcinoma A549 Cells to Cisplatin". *SCIENCE IN CHINA (Series C)*, 44 (1):25-32.
- Lim, E.L. dan Marra, M.A., 2013, "MicroRNA Dysregulation in B-cell Non Hodgkin Lymphoma", *Blood and Lymphatic Cancer: Targets and Therapy*, 3:25-40.
- Livak, K.J. dan Schmittgen, T.D., 2001, "Analyses of Relative Gene Expression Data Using Real-Time Quantitative PCR and The 2- Ct Method", *Methods*, 25: 402–408.
- Lu, D., Shi, H-C., Wang, Z-X., Gu, X-W., Zeng, Y.J., 2012, "Multidrug Resistance-Associated Biomarkers P-GP, GST-pi, Topo-II and LRP as Prognostic Factors in Primary Ovarian Carcinoma", *Mol Cancer Ther.*, 11:492.
- Manne, U., Srivastava, R-G., Srivastava, S., 2005, "Recent Advances in Biomarkers for Cancer Diagnosis and Treatment", *DDT*, 10(14):965-976.
- Marshall, L. dan White, R.J., 2008, "Non-coding RNA Production by RNA Polymerase III is Implicated in Cancer", *Nat Rev Cancer.*, 8:911–914.
- Mathews, D. H., 2005, "Predicting a Set of Minimal Free Energy RNA Secondary Structures Common to Two Sequences". *Bioinformatics Original Paper*. 21(10): 2246–2253.
- Motsch, N., Pfuhl, T., Mrazek, J., Barth, S., Grässer, F.A., 2007, "Epstein-Barr Virus-Encoded Latent Membrane Protein 1 (LMP1) Induces The Expression of The Cellular microRNA miR-146a, *RNA Biol.*, 4(3):131-7.
- Moussay, E., Palissot, V., Vallar, L., Poiriel, H.A., Wenner, T., El Khoury, V., Aouali, N., Van Moer, K., Leners, B., Bernardin, F., Muller, A., Cornillet-Lefebvre, P., Delmer, A., Duhem, C., Ries, F., van Dyck, E., Berchem, G., 2010, "Determination of Genes and MicroRNAs Involved in the Resistance to Fludarabine In Vivo in Chronic Lymphocytic Leukemia", *Mol Cancer*, 9: 115.
- Murata, A., Fukuzumi, T., Umemoto, S., Nakatani, K., 2013, "Xanthone Derivatives as Potential Inhibitors of miRNA Processing by Human Dicer: Targeting Secondary Structures of Pre-miRNA by Small Molecules", *Bioorganic & Medicinal Chemistry Letters*, 23: 252–255.



Nagai, H., Kinoshita T., Ichikawa A., Murate T., 2002, "Malignant Lymphoma and Tumor Suppressor Genes", *J. Clin. Exp Haematopathol.*, 42(1):11-24.

National Cancers Institute, 2014, NCI Dictionary of Cancer Terms (internet) <<http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/ncidictionaries>> (diakses: 1 April 2014).

Noonberg, S.B., Scott, G.K., Benz, C.C., 1996, "Evidence of Post-Transcriptional Regulation of U6 Small Nuclear RNA", *J Biol Chem.*, 3; 271(18):10477-81.

Ohsawa, M., Ikura, Y., Fukushima, H., Shirai, N., Sugama, Y., Suekane, T., Hirayama, M., Hino, M., Ueda, M., 2005, "Immunohistochemical Expression of Multidrug Resistance Proteins as a Predictor of Poor Response to Chemotherapy and Prognosis in Patients with Nodal Diffuse Large B-cell Lymphoma", *Oncology*, 68(4-6):422.

Ok, C.Y., Papathomas T.G., Medeiros L. J., Young K.H., 2013, "EBV-Positive Diffuse Large B-Cell Lymphoma of The Elderly", *Blood*, 122(3):328-40.

Orang, A. V., Reza S., Kazemzadeh, B. M., 2014, "Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation", *International Journal of Genomics*, 2014:970607.

Planchon, S.M., Waite, K.A., Eng, C., 2008, "The Nuclear Affairs of PTEN", *J Cell Sci.*, 121: 249-253.

Raddaoui, E., Alhamad, E.H., Zaidi, S.N., Al-Habeeb, F.F., Arafah, M., 2014, "Utility and Diagnostic Accuracy of Endobronchial Ultrasound-Guided Transbronchial Fine-Needle Aspiration Cytology of Mediastinal Lesions: Saudi Arabian Experience", *CytoJournal* , 11:19.

Radel, S., Fredericks, W., Mayhew, E. Baker, R., 1990, "P-glycoprotein Expression and Modulation of Cell-Membrane Morphology in Adriamycin-Resistant P388 Leukemia Cells", *Cancer Chemotherapy and Pharmacology*, 25: 241-246.

Roberti A, D. La Sala, Cinti, C., 2006, "Multiple Genetic and Epigenetic Interacting Mechanisms Contribute to Clonally Selection of Drug-Resistant Tumors: Current Views and New Therapeutic Prospective", *J Cell Physiol.*, 207:571-81.

Roepe, P. D., Wei, L. Y., Cruz, J., Carlson, D, 1993, "Lower Electrical Membrane Potential and Altered pHi Homeostasis in Multidrug-Resistant (MDR)

Cells: Further Characterization of a Series of MDR Cell Lines Expressing Different Levels of P-glycoprotein”, *Biochemistry*, 32: 11042-11056.

Rosato, P., Anastasiadou, E., Garg, N., Lenze, D., Boccellato, F., Vincenti, S., Severa, M., Coccia, E.M., Bigi, R., Cirone, M., Ferretti, E., Campese A.F., Hummel M., Frati, L., Presutti, C., Faggioni, A., Trivedi P., 2012, “Differential Regulation of *miR-21* and *miR-146a* by Epstein–Barr Virus-Encoded EBNA2”, *Leukemia*, 26: 2343–2352.

Rossi, S., Shimizu, M., Barbarotto, E., Nicoloso, M.S., Dimitri, F., Sampath, D., Fabbri, M., Lerner, S., Barron, L.L., Rassenti, L.Z, Jiang, L. Xiao, L., Hu, J., Secchiero, P., Zauli, G., Volinia, S., Negrini, M., Wierda, W., Kipps, T.J., Plunkett, W., Coombes, K.R., Abruzzo, L.V., Keating, M.J., Calin, G.A., 2010, “MicroRNA Fingerprinting of CLL Patients with Chromosome 17p Deletion Identify a *miR-21* Score that Stratifies Early Survival”, *Blood*, 116: 945-52.

Sa’adah, N. Astuti, I., Haryana, S.M., 2014, Ekspresi *microRNA 451* dan P-glycoprotein pada Raji *Cell Line* Resistensi *Doxorubicin*, Tesis: UGM, Yogyakarta.

Saber, M., Shamaa, S., El-Serafi, M., Moktar, N., Lorigan, P., Mohamad E. L., 2000, “P-Glycoprotein (P-gp) Expression in Resistant or Relapsing Hodgkin’s Disease”, *J Egypt Nat Cancer Inst.*, 12 (1): 41–50.

Sánchez-Espiridión, B., Martín-Moreno, A. M., Montalbán, C., Figueroa, V., Vega, F., Younes, A., Medeiros, L. J., Alvés, F. J., Canales, M., Estévez, M., Menarguez, J., Sabín, P., Ruiz-Marcellán, M. C., Lopez, A., Sánchez-Godoy, P., Burgos, F., Santonja, C., López, J. L., Piris, M. A., Garcia, J. F., 2013, “MicroRNA Signatures and Treatment Response in Patients with Advanced Classical Hodgkin Lymphoma”, *British Journal of Haematology*, 162: 336–347.

Sandor, V., Wilson, W., Fojo, T., Bates, S.E., 1997, “The Role of MDR-1 in Refractory Lymphoma”, *Leuk Lymphoma*, 28(1-2):23-31.

Schmitz, 2014, “Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics”, *Nature*, 490(7418):116-120.

Sehn, L.H., Berry, B., Chhanabai, M., Fitzgerald, C., Gill, K., Hoskins P., 2007, “The Revised International Prognostic Index (R-IPI) is a Better Predictor of Outcome than the Standars IPI for Patients with Diffuse Large B-Cell Lymphoma treated with R-CHOP”, *Blood*, 109:1857-61.

Seminar Nasional Peluang dan Tantangan Obat Tradisional dalam Pelayanan Kesehatan Formal, FK UGM, 2013, Development of a 5-Fluorouracil



Acquired Resistance WiDr Colon Cancer Cell Line, Kartika, Y.D., Astuti, I., Woro R.P., Yogyakarta: FK UGM.

Sheedy, F. J., 2015, "Turning 21: Induction of *miR-21* as a Key Switch in the Inflammatory Response", *Front Immunol.*, 6:19.

Shen, H., Xu, W., Luo, W., Zhou, L., Yong, W., Chen, F., Wu, C., Chen, Q., Han, X., 2011, "Up Regulation of MDR1 Gene is Related to Activation of The MAPK/ERK Signal Transduction Pathway and YB-1 Nuclear Translocation in B-cell Lymphoma", *Exp Hematol.*, 39(5):558-69.

Shen, H., Zhu F., Liu J., Xu. T., Pei D., 2014, "Alteration in *mir-21*/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer", *PLoS ONE* 9(7): e103305.

Simon, S. M., Schindler, M., 1994, "Cell Biological Mechanisms of Multidrug Resistance in Tumors", *Proc. Natl. Acad. Sci. U.S.A.*, 91: 3497-3504.

Sonkoly, E., Wei, T., Janson, P. C. J., Saaf, A., Lundeberg, L., Tengvall-Linder, M., Norstedt, G., Alenius, H., Homey, B., Scheynius, A., Stahle, M., Pivarcsi, A., 2007, "MicroRNAs: Novel Regulators Involved in The Pathogenesis of Psoriasis?", *PLoS One*, 7: 610.

Steelman, L.S., Franklin R. A. , Abrams S. L. , Chappell W. , Kempf C. R., Bäsecke J. , Stivala F., Donia M. , Fagone P. , Nicoletti F., Libra M. , Ruvolo P. , Ruvolo V. , Evangelisti C., Martelli A.M., McCubrey J.A., 2014, "Roles of The Ras/Raf/MEK/ERK Pathway in Leukemia Therapy", *Leukemia*, 25(7):1080-94.

Stern R. G., Milestone B. N., Gatenby R. A., 1999, "Carcinogenesis and The Plasma Membrane", *Med. Hypotheses*, 52: 367-372.

Strimbu, K. dan Tavel, J. A. 2010, "What are Biomarkers?", *Curr Opin HIV AIDS*, 5(6): 463–466.

Szakács, G., Paterson, J. K., Ludwig, J. A., Genthe, C. B., Gottesman, M. M., 2006, "Targeting Multidrug Resistance in Cancer", *Nat. Rev. Drug Discov.*, 5:219–234.

Toprak, A. B., Vatansever, S., Kemal, Ö.Z.B., 2006, "Computer Assisted Image Analysis of Peroxidase Stained Endometrial Tissue", *Turk J Med Sci.*, 36 (5): 285-290.

Ullah, M.F., 2008, "Cancer Multi Drug Resistance (MDR): a Major Impediment to Effective Chemotherapy", *AsianPac.J.CancerPrev.*, 9:1–6.

Volinia, S., Calin, G., Liu, C.G., 2006, “a MicroRNA Expression Signature of Human Solid Tumors Defines Cancer Gene Targets”, *Proc Natl Acad Sci USA*, 103:2257–61.

Vrekoussis, T., Chaniotis, V., Navrozoglou, I., Dousias, V., Pavlakis, K., Stathopoulos, E.N., Zoras, O., 2009, “Image Analysis of Breast Cancer Immunohistochemistry Stained Sections Using *ImageJ*: An RGB-based Model”, *Anticancer Research*, 29: 4995-4998.

Vrie, W. V. D., 1997, “Modulation of P-Glycoprotein-Mediated Multi Drug Resistance in The CC531 Rat Colon Tumor Model”, Thesis:Erasmus Universiteit Rotterdam.

WHO dan International Agency for Research on Cancer (IARC), 2013, Global Cancer Facts & Figures 2nd Edition. <[www.cancer.org/research/cancerfactsstatistics/global-cancer-facts-figures-2nd-edition.pdf](http://www.cancer.org/research/cancerfactsstatistics/global-cancer-facts-figures-2nd-edition.pdf)> (diakses: 1 April 2014).

Witkos, T.M., Koscianska, E., Krzyzosiak W.J., 2011, “Practical Aspects of microRNA Target Prediction Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation”, *Current Molecular Medicine*, 11: 93-109.

Yamanaka, Y., Tagawa, H., Takahashi, N., Watanabe, A., Guo, Y-M, Iwamoto K., Yamashita, J., Saitoh, H., Kameoka, Y., Shimizu, N., Ichinohasama, R. Sawada, K-I., 2009, “Aberrant Overexpression of microRNAs Activate AKT Signaling via Down-Regulation of Tumor Suppressors in Natural Killer–Cell Lymphoma/Leukemia”, *Blood*, 114(15): 3265-75.

Yang, G.D., Huang, T.J., Peng, L.X., Yang, C.F., Liu, R.Y., 2013, “Epstein-Barr Virus Encoded LMP1 Upregulates *microRNA-21* to Promote the Resistance of Nasopharyngeal Carcinoma Cells to Cisplatin-Induced Apoptosis by Suppressing PDCD4 and Fas-L”, *PLoS ONE*, 8(10): e78355.

Zahreddine H. dan Barden L.B., 2013, “Mechanisms and Insight into Drug Resistance in Cancer”, *Frontiers in Pharmacology*, 4:28.

Zajchowski, D.A., Karlan, B.Y., Shawver, L.K., 2012, “Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas”, *Mol Cancer Ther.*, 11(2):492-502.

Zheng, R.L., Jiang, Y-J., Wang, X., 2014, “Role of MicroRNAs on Therapy Resistance in Non-Hodgkin’s Lymphoma”, *Int J Clin Exp Med.*, 7(11):3818-3832.